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With the event of new Molecular targets, clinical trial design requirements to perform
these trials are changing. This paper discusses some of the considerations that need to
be taken into account when designing a trial, including those trials that assess combina-
tions of targets.
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Published by Elsevier B.V. All rights reserved.1. Introduction survival or overall survival benefit are sufficient to enable reg-The rapidly increasing knowledge in tumor biology has
changed drug development importantly and has brought per-
sonalized medicine closer to reality. Better than before are we
able to identify patient populations with tumors that harbour
specific molecular alterations. If these molecular alterations
are truly tumor growth driving factors, then their inhibition
should lead to inhibition of tumor growth. That means that
establishing the functionality of an assumed growth factor is
crucial before even starting clinical research on a molecularly
targeted therapy that aims to inhibit this factor. It also means
that without evidence of inhibition of the target following ad-
ministration of the drug of interest, we may consider to halt
development of that drug.
A problem in oncology is the lack of short-term endpoints
of treatment. For this reason usually only progression-free(J. Verweij).
ation of European Biocheistration of the drug. This is completely different from other
fields of healthcare where drugs can be registered upon
short-term endpoint benefit. Downsides of the latter approach
are the possibility that the effect on the short-term endpoint
may not lead to relevant ultimate health benefits and the
risk of withdrawal from registration based upon late occurring
side effects, a withdrawal that hardly ever occurs in oncology.
For early decision making it is thus important to try and
rely on surrogate or intermediate endpoints. In order to en-
sure we are all on the same page concerning the terminology
used, we would like to use the term “proof of mechanism” for
any evidence that shows that a new drug inhibits its assumed
molecular target. If that target is truly functional for tumor
growth, the inhibition should affect cell kinetics. This could
be termed “proof of principle”. If the effects on cell kinetics are
sufficient, inhibition of a truly functional growth factor shouldmical Societies. Published by Elsevier B.V. All rights reserved.
Table 2 e Expected problems and consequences for trial design.
Chronic dosing
required
/adjust DLT period and DLT criteria
PK interaction /Include formal drug interaction
assessment in the phase I study
PD interaction /3þ3þ3 design
/Implementation of control group
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by anatomic size changes or validated functional imaging.
This could be termed “proof of concept”. Each of these proofs
could have a related biomarker, the pharmacodynamic, pre-
dictive (that can be used for patient selection), and the bio-
marker of cancer growth, respectively (Tables 1 and 2).
Given the costs involved in drug development, the abun-
dance of new chemical entities in development, the increas-
ing discussion in society on drug cost-effectiveness, and the
limitations of affordability, we need to find all types of “proof
of” as early as possible, and try to predict Drug-Registration al-
ready in the earliest clinical studies (Fuchs, 2011; Sleijfer and
Verweij, 2009). This will be possible by designing smart, selec-
tive and specific clinical trials. This chapter will put current is-
sues in designing clinical trials of molecularly targeted drugs
eventually leading to approval, into perspective.2. The preclinical information required prior to start
of an early clinical trial: functionality of the target
The information we used to require prior to exposing human
beings to a new chemical entity has not been changed with
the emergence of molecularly targeted drugs. Here we will
not discuss the obvious requirements of activity in models,
safety in animals etc. But it is important to stress that since
the early clinical trial will gain importance, andwill be seeking
selection of a better defined populations of individuals based
upon detailed tumor characteristics, we will need even more
specific information prior to clinical trial start.
Since we are targeting specific molecular alterations, we
will first have to convince ourselves of their functional rele-
vance in driving tumor growth (Verweij, 2008). Unfortunately
as far as tumor cell related targets are concerned, the cur-
rently available preclinical models do require optimization
given their lack of resemblance with the human situation.
They are evenmore limited in predictability for targets located
outside tumor cells, in the tumor environment. Yet, only this
type of information will enable us to take Go/NoeGo decisions
on further development at the end of the first clinical studies,
andwill enable us to develop all of the biomarkers required for
rapid drug development.Table 1 e Biomarkers in drug development.
Pharmacodynamic biomarkers (Proof of Mechanism):
 To prove a drug inhibits its putative target
 In surrogate tissues (with major limitations)
 In tumor tissues
 To help assign an optimal dose/schedule for
efficacy evaluations
Predictive biomarkers (Proof of Principle):
 To select patients most (or least) likely to benefit
Biomarkers of cancer growth (Proof of Concept):
 To reflect changes in tumor’s anatomical and
biological growth3. Trial design and flowerapid movement to
registration trials
In case of development of a drug with a well-defined func-
tional molecular target, proven to be inhibited in the preclini-
cal studies, the clinical studies can be focused by rigorously
selecting patients whose tumors harbour the essential molec-
ular change. Developing and assessing the so-called “selection
biomarker” or “proof of principle” biomarker is thus crucial for
this purpose. Nice examples can be found in the use of c-KIT
mutations for GIST and EML4-ALK mutations for non-small
cell lung cancer (Verweij et al., 2004; Kwak et al., 2010). Since
it starts to become evident that molecular changes in tumors
evolve over time, and that thus the characteristics of primary
tumors may be different from those of metastases, it will be-
come increasingly important to use actual tumor materials,
i.e. a biopsy of either the primary tumor or the metastases
depending on the disease stage treated, or circulating tumor
cells in which characterization in great detail is nowadays
also possible (Sleijfer et al., 2007; Sieuwerts et al., 2011). The
latter use would avoid the practical hurdles that some have
reported in performing repeat biopsies. While there are
some examples of concordance of biomarker expression be-
tween primary and metastatic sites, in the majority of cases
of metastatic disease, working with primary tumor tissue
will likely no longer be adequate.
The evolving personalized treatment trial design for this
scenario will be selection of patients based on tumor charac-
teristics and only patients with the requested tumor charac-
teristic will be entered on study. If the preclinical data are
adequate, this means that the dose seeking part of develop-
ment can even be combined with the screening for activity
part. In older terms: the phase I and II study parts can be com-
bined. If such a combined study then fails to show sufficient
evidence of antitumor activity, clinical development should
be halted and the drug could be brought back to the preclinical
stage of research.
While previously the so-called “expanded cohort” mainly
served the purpose of better defining pharmacokinetics and
ensuring safety at the dose recommended for phase II studies,
this cohort can also serve to screen for antitumor activity. The
development and subsequent results of Imatinib for CML and
GIST, Vismodegib for metastatic basal cell carcinoma of the
skin and crizotinib for EML4-ALK fusion protein harbouring
non-small-cell lung cancer, respectively, may serve as exam-
ples (Verweij et al., 2004; van Oosterom et al., 2001; Von Hoff
et al., 2009).
In case the evidence of assumed functionality of themolec-
ular target cannot convincingly be provided, and thus a higher
level of uncertainty concerning the target may be considered,
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account to confirm that a first-in-class drug inhibits its puta-
tive biological target, particularly when a new mechanism of
action (or resistance) is revealed. If the evidence of clinical ef-
ficacy is unclear, evidence of target engagement in tumor tis-
sues (or lack thereof) can be informative, and be mainly used
for a NoeGo decision should the target be inhibited insuffi-
ciently as compared to preclinical information on required in-
hibition in relation to tumor size effects.
One of the best validated pharmacodynamic markers re-
mains the use of sizemeasurement of existing tumor deposits
(Verweij et al., 2009). Certainly if there is tumor regression as
classified by RECIST, this can be taken as evidence of target in-
hibition (Eisenhauer et al., 2009). True stable disease (so no
real change in tumor size) is less easy to assess, since it can
also reflect the natural history of disease, certainly in case of
slowly growing tumors. However, if the study aims to include
proof of tumor growth in the individual prior to study entry,
evidenced by making radiology studies available for the 4e6
months prior to study entry, a change in tumor growth dy-
namics can in theory be assessed and taken as evidence of tar-
get inhibition. This can either be by calculating the ratio of the
time to tumor progression on study to the time to tumor pro-
gression on the treatment given prior to study entry, or alter-
natively by using the patient as its own control (Mick et al.,
2000; Sonpavde et al., 2009).
Just like in case of well-defined molecular target function-
ality, also in this scenario combination of phase I and phase II
elements can be pursued early on. Yet some kind of limited
formal phase II development may be required. It is conceiv-
able that in this scenario we need to pursue randomization
early; either as a randomized discontinuation design or alter-
natively as a formal randomized phase II study, to decrease
the financial risks related to a failed phase III study (Stadler
and Ratain, 2000).
This brings us to the general cost issue. In drug develop-
ment we can no longer ignore the consequences of our previ-
ous designs on the resulting costs of our treatments. The
smaller the benefit we are looking for, the larger the trials
will have to be, and thus the more costly drug development
will be (Stewart and Kurzrock, 2009; Sobrero and Bruzzi,
2009). We may therefore be forced to limit our studies in aim-
ing for a large magnitude of effect, which can be proven in
a relatively robust way by a trial with a relatively small sample
size.4. Pharmacological aspects
From a pharmacology perspective it is also important to stress
specific aspects of the early clinical trial. In essence proper
pharmacologic information will be the basis of proper devel-
opment decisions. Correlating drug exposure to other out-
come parameters can lead to individual treatment decisions.
So in performing early clinical trials the use of real time phar-
macokinetics is crucial to help guide Go/NoeGo decisions
(Soepenberg et al., 2004; de Jonge et al., 2010; LoRusso et al.,
2011).
For oral drugs the relevance of food effect and bioavailabil-
ity information early on in development has been publishedbefore, wherewe have advocated the design of amultipurpose
study (Verweij, 2008). Without early food effect studies it is
highly likely that major marketing strategies will go wrong.
For instance the marketing approval for lapatinib and abira-
terone involves a dose that can possibly and largely be low-
ered without loosing activity, by taking the drug at
appropriate times relative to food intake (Ratain and Cohen,
2007). Assessment of drug scheduling is impractical during
the clinical phase and should be performed in models.5. Issues of multiple simultaneous targets
In the (patho)physiology of cancer cells, a complex network of
transmembrane receptors and receptor driven and mutually
interactive intracellular signal transduction pathways is re-
sponsible for the malignant and/or invasive phenotype. For
the majority of cancer cells, and hence human tumors, it is
virtually impossible to point at one single receptor, intracellu-
lar pathway or signal protein whose abnormal functioning is
solely and exclusively driving this phenotype. In the cases
where, however, this seems possible, it is conceivable that
due to genetic instability alternative receptors or pathways
may become sequentially responsible for the malignant phe-
notype at various times during the course of the disease. It
is conceivable that these changes might be responsible for
emerging drug resistance during treatment.
Most target inhibitory anticancer agents exert biological
activity (‘proof of mechanism’) at a specific place within the
cellular signal transduction network. While monoclonal anti-
bodies are usually highly target selective, small molecule tar-
get inhibitory agents can be more or less selective in their
target affinity.
Considering the complexity and interactivity of the intra-
cellular signal transduction network, it is difficult to envision
that single target inhibitors would be able to durably and con-
sistently inhibit overall signal transduction activity and thus
show convincing proof of concept. Still, andmaybe somewhat
counterintuitive, clinical evidence exists that some target-
specific inhibitors, be it monoclonal antibodies or small mole-
cule inhibitors, have shown proof of concept in such malig-
nancies as GIST, CML, HER2 positive breast cancer, renal cell
carcinoma, BRAF mutated melanoma, and non-small cell
lung cancer harbouring eithermutated Epidermal Growth Fac-
tor receptors or oncogenic fusion genes consisting of EML4
and anaplastic lymphoma kinase (ALK) (Verweij et al., 2004;
Kwak et al., 2010; O’Brien et al., 2003; Slamon et al., 2001;
Motzer et al., 2008, 2009; Hudes et al., 2007; Robert et al.,
2011; Chapman et al., 2011; Jonker et al., 2007; Mok et al.,
2009). While single target inhibition in these circumstances
has shownmeaningful clinical efficacy, for themajority of hu-
man tumors such an approach has not (yet) proven to be very
effective.
Given the described complexity and interactivity of the sig-
nal transduction network, it may be more rational to try to in-
hibit more than one target or pathway at a time. As nowadays
a large number of biologically active single target inhibitory
compounds are available, a great variety of concomitant com-
bined approaches can be considered. For this reason, and here
only given as examples of this approach, combined inhibition
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PI3K-AKT-mTOR pathway, as well as combined inhibition of
the C-Met and EGFR pathway are currently being explored.
Even though large randomized phase III trials with well-de-
fined endpoints such as progression-free and overall survival
have started to enrol patients, a large number of these drug
combination studies are focussing on short-term endpoints
such as demonstration of proofs of mechanism and proof of
principle. If the outcomes of these studies are convincing,
the pivotal randomized phase III studies will subsequently
have to be performed in order to prove these effects on overall
survival. As, especially in well-selected patient populations, it
can be anticipated that prolonged periods of treatment will
probably have to be given in order to demonstrate and sustain
effect, issues of optimal drug tolerance and treatment adher-
ence deserve great attention. In the following we will provide
additional considerations on some important aspects of target
inhibitory drug development and study design.
When considering simultaneous multitarget or multipath-
way inhibition, the question is whether the application of
a combination of single target or small spectrum inhibitory
agents should be favoured, allowing for flexibility of adminis-
tration of each compound, or whether one broad target inhib-
iting agent should be preferred. The latter would probably
increase patient convenience and treatment adherence and
avoid drugedrug interactions with their chance of negative al-
teration of drug activity or increased likelihood of side effects.
Here parallels with prolonged treatment approaches in some
non-malignant chronic diseases could be drawn (Ratain
et al., 2008).
Decades of experience how to control actual signs and
symptoms of the underlying diseases, and knowledge which
targets or receptors could best be blocked in their activity,
have enabled successful development of multitarget inhibi-
tion or combinational approaches of hypertension and diabe-
tes. With treatments that most often have to be given forever,
adherence is a major challenge, and ease and simplicity of
drug administration is thus key.
Projecting the single agent “multi-hit” treatment paradigm
to cancer would lead to favour the use of single agent therapy
with broad spectrum target inhibition. However, onewill have
to take into account that the genetically instable nature ofma-
lignant disease differs from the more stable nature of most if
not all of the mentioned non-malignant diseases, where sec-
ond and subsequent lines of treatment can accomplish effec-
tivity that is comparable to first line treatment.
With an eye on resistance development one could hypoth-
esize that combined inhibition of multiple targets at the same
time is a negative. This is currently unknown. However, if this
would be the case it is conceivable that a stepwise target inhi-
bition (subsequent, rather than multiple at the same time)
might be useful. With regard to the pro’s and cons of concom-
itant or sequential treatment, some considerations come into
play.
First of all it is important to realize in the concept of growth
inhibition, the aim becomes to turn cancer into a chronic dis-
ease with disease control while maintaining quality of life,
throughout long periods of treatment. Thus pursuingmeasur-
able tumor shrinkage becomes less an endpoint, whereas de-
creasing tumor viability and stabilizing its anatomical sizebecomes the new endpoint. This means that disease- or
progression-free survival will become very important end-
points in clinical oncology trials. In patients with hormone re-
ceptor positive metastatic breast cancer, the paradigm of
sequentially treating that patient with different target inhibi-
tory agents in order to prolong disease-free survival is already
routine daily practice, but also for cytotoxic treatment these
aims seem to hold in diseases as colorectal carcinoma, non-
small cell lung cancer and (albeit maybe less convincing)
breast cancer (Koopman et al., 2007; Marsland et al., 2005;
Felip et al., 1998; Carrick et al., 2009; de Bono and Ashworth,
2010).
Second, given the fact that within the currently unravelled
signal transduction network system a very large number of re-
ceptors and intracellular proteins are considered to be poten-
tial targets for specific inhibitory agents, a tremendous
number of compounds and combinations become conceiv-
able. Choices will therefore have to be made, as resources
will hamper full testing of all theoretical possible
combinations.
A final issue that could be considered when exploring the
role of all these individual pathways and receptors is whether
there chronological relationship between them in the cell-
cycle order of events. For many routinely used cytotoxic
agents, combination regimens are indeed based upon such
considerations. If membrane bound and cytoplasmatic target
processes were just as chronologically dependent on each
other, it may be that certain administration sequences are
most effective. Even though currently there is no indication
of such ‘sequence driven’ target inhibition interplay, studies
assessing this have recently.
In the current highly competitive field, target affinity has
been suggested to provide distinction. Currently, however,
there is no clinical evidence that higher target affinities pre-
dict superior clinical activity. That is, the actual pharmacoki-
netic behaviour and absence or pharmacokinetic
interactions might possibly be more predictive for biological
and clinical activity, and pharmacokineticepharmacody-
namic correlations should be determined as much and as
early as possible throughout clinical development for any tar-
get inhibitory agent irrespective its inhibitory profile.
The optimal target inhibitory strategy for a given patient
should no longer solely depend on the availability of agents,
but should preferentially be guided by a thorough and re-
peated analysis of the role and activity of the various targets
that are inducing the malignant phenotype of the tumor.
The optimal design for studies that are exploring the added
value of these target inhibitory strategies in populations of pa-
tients should take into consideration the selection of patients
based upon (repeated) molecular analyses, and should con-
sider the assessment of repeated periods of progression-free
survival rather than focussing on a single period of overall sur-
vival following the first line of treatment.6. Rational drug combinations
As mentioned before, although several tumor growth driving
mutations have been identified for which inhibition of the tar-
get results in tumor shrinkage, in most tumors the genetic
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waywill not lead to sustained tumor growth inhibition. There-
fore combined interference with different but related tumor
targets is pursued. As already stated, the large number of
new agents registered and still in development could result
in a vast amount of two-drug combinations. Not to mention
the possibility to combine targeted agents with classical che-
motherapy and 3 or 4 drug combinations. Due to our restric-
tions both in budget and time, choices will continuously
have to bemade to prioritize the combinations to study. In for-
mer days choices for combining cytotoxic agents were based
on single agent activity in a certain tumor types and non-
overlapping toxicities. In addition preclinical evidence of addi-
tive or synergistic activity for the combination provided the
rationale for performing clinical studies. Also for the combina-
tion of small molecularly targeted agents preclinical evidence
should demonstrate at least additive effects of both agents.
However, presently our preclinical models do not adequately
predict efficacy of combinations of targeted agents in the
clinic. Cancer cell lines have been adapted to grow in the lab-
oratory andmay not be indicative of the actual tumor they are
meant to represent; they are frequently genetically very ill-de-
fined, there is a potential mismatch between human tumor
cells and mouse stroma, a severely compromised immune
system in the host animal, while the endpoints used in these
preclinical experiments are often ill-defined (de Bono and
Ashworth, 2010). In order to improve our preclinical screening
tools the NCI initiated an in vitro combination drug screen that
accommodates testing of rationally designed choices but also
allows for serendipity (Kummar et al., 2010).
From a theoretical point of view the combination of agents
targeting a single crucial target in the cancer cell aiming to op-
timize target inhibition, the same pathway or intersecting
pathways are compelling (Hamberg and Verweij, 2009).
This approach would imply that we have full understand-
ing of the mechanism of action, resistance and interaction
of the administered agents already prior to the phase I studies
also enabling selection of patients based on their specific tu-
mor characteristics to enrich the study population. Unfortu-
nately this is not always the case as exemplified by the
requirement of EGFR expression in the early studies for the
presumed efficacy of cetuximab and erlotinib, and the devel-
opment of BRAF inhibitors (Ratain and Glassman, 2007). De-
spite the limitations, and as discussed above, in specific
circumstances the implementation of biomarkers may help
in phase I studies to establish target inhibition in a given
dose range.
Actually, most likely targeting different pathways simulta-
neously may be most optimal for improving the outcome for
the patient.
The design of combination phase I studies is also crucial.
Given the fact the most targeted agents are administered
orally on a chronic basis, the classical phase I design is no lon-
ger appropriate. For the combination of targeted agents
chronic dosing and therefore cumulative toxicity is as impor-
tant as the toxicities observed in the acute phase, often the
first 3 to 4 weeks of treatment. Also due to the aimed chronic
administration of these drugs the definition of dose limiting
toxicities (DLTs) should be adjusted. Patients will tolerate
short periods of i.e. grade 2 non-haematological toxicities.However, for prolonged periods of time, chronic grade 2
non-haematological toxicities might be intolerable. In case
of a combination of drugs an intermittent schedule may be
most optimal to maximize target inhibition in balance with
acceptable toxicities (Kummar et al., 2010).
For several combinations involving targeted agents (for in-
stance the combination of VEGF-based multi-tyrosine kinase
inhibitors with all kinds of cytotoxics) unexpectedly enhanced
toxicity was observed allowing only dosing at doses that are
quite lower than each of the respective single agent doses. Es-
pecially agents targeting the same pathway tend to induce in-
creased toxicity preventing full dosing of either agent.
Combinations with monoclonal antibodies seem better toler-
ated. Unfortunately data on mechanism of toxicity are lim-
ited, thereby preventing our abilities to predict the safety of
a given combination of drugs (Kummar et al., 2010). In case
dose reductions are necessary to enable combination treat-
ment of targeted agents, it becomes extremely important to
incorporate measurements of biomarkers in the phase I stud-
ies in order to assess adequately maintained target inhibition.
Phase I trial design will also be dictated by the anticipated
interaction between the administered agents. In case a phar-
macokinetic (PK) interaction is expected, which we observe
more often with the combination of orally administered
agents, extensive PK sampling should be incorporated during
the phase I study. In order to compare the PK data for the com-
bination with single agent data also PK for the single agents
will have to be assessed (Hamberg et al., 2010). If a pharmaco-
dynamics interaction is anticipated these should be optimally
monitored.
For combination therapies different Maximum Tolerated
Doses (MTDs) can be established dependent on the schedule
of administration used, choices made to dose one of the
agents at single agent dose and escalation steps used allowing
optimal dosing of one of the agents in the combination
(Hamberg et al., 2010). One must be aware of the conse-
quences of the choices made in the study design used on the
determined MTDs.
Another challenge that has to be tackled in combination
phase I studies is to discern the real toxicity of the combina-
tion from the background toxicity attributable to each of the
components in that combination, which by chance can be
higher than is expected based on historical data. There are
several options to define the toxicity attributed to the combi-
nation more precisely (Hamberg and Verweij, 2009; Hamberg
et al., 2010). By using the classical 3þ3 design the chance of
halting the dose escalation falsely due to the effect of chance
will increase with a higher incidence of unknown but true se-
vere toxicity. This might especially impose a problem when
cytotoxics are combined with targeted agents. By expanding
the dosing cohorts from 6 to 9 patients the chance of halting
the dose escalation falsely can be largely reduced. Another op-
tion to reduce the influence of chance on the outcome of the
phase I combination study is the introduction of a control pop-
ulation. Patients can either be used as their own control, by
administering the first cycle with a single agent only and com-
pare the toxicity observedwith the toxicity in the second cycle
with the combination therapy. Another option would be to in-
troduce a randomization in the phase I study between single
agent and combination therapy. Both options might also be
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apy in the first cycle will be treated with the combination
from the second cycle onwards. As stated these adaptations
in trial design are most applicable for combinations with an
expected high incidence of severe toxicity and when overlap-
ping toxicity of the combining agents is expected.
As stated already, for combination therapy randomized
phase II studies are essential in order to evaluate antitumor
efficacy. Since several MTDs for a combination may be identi-
fied these should be studied in randomised phase II studies
also allowing for a dose range with biological activity. It is es-
sential to perform these studies in patient populations se-
lected on the basis of tumor characteristics in order to
increase the possible benefit of treatment. Due to our financial
restrictionswewill have to focus onmore robust treatment ef-
fects allowing studies with smaller sample size both in phase
II and III developments.7. Regulatory issues
Regulatory decision making is a very delicate process. On the
one hand, novel treatments yielding superior clinical benefit
over available therapies should be made available to patients
as early as possible. On the other hand, however, inactive
treatments must be prevented to come on the market as this
will expose patients to toxicity from inactive therapies, may
block evaluation of other novel, potentially active treatments,
and will lead to increased health care costs.
The highest level of certainty whether or not a novel ther-
apy improves outcome in cancer patients can be obtained
from a randomized phase III trial with overall survival (OS)
as primary study endpoint. Accordingly, such trials preferably
form the basis for decision making by regulatory agencies
such as the US Food and Drug Administration (FDA) and the
European Medicines Agency (EMA). However, since OS as
a study endpoint may take long to establish and a potential
OS difference between two treatment approaches can be se-
verely obscured by active post-study treatments, surrogate
endpoints for clinical benefit are increasingly used and ac-
cepted by regulatory agencies for approval. Examples of these
endpoints include disease-free survival (DFS) for adjuvant
therapies, progression-free survival (PFS) for the metastatic
setting, and quality of life parameters, the latter in terms of
pain relief or prevention/attenuation of toxicity from treat-
ment. Taken as an example of the latter, dexrazoxane was ap-
proved for anthracycline-induced cardiomyopathy. However,
such surrogate endpoints for clinical benefit are difficult to in-
terpret. With exception of DFS in breast and colon cancer, it is
unknownwhether a prolongation in DFS or PFS translates into
a true clinical benefit, and if so, what the magnitude of differ-
ence between two treatments should be. This uncertainty ac-
counts largely for the frequent differences in approved
indications between the FDA and EMA. A recent study
revealed that for 42 anticancer drugs approved for 100 differ-
ent indications by the EMA, there were differences in FDA reg-
istration for 47 of the 100 indications. Out of these, 19
indications were only approved by one agency (Trotta et al.,
2011).The successes obtained with molecular targeted drugs in
selected cancer populations have added another level of com-
plexity. Based on the identification of tumor-driving factors in
an increasing number of tumor types, the availability of drugs
effectively inhibiting the function of these factors, and tools
enabling the identification of patients with tumors harbouring
the target of interest, we nowadays sometimes see impres-
sively and unprecedentedly improved antitumor activity in
terms of response rate, PFS, and OS already in single-arm,
early clinical trials. Recent examples include the studies on
vemurafenib (PLX4032) in patients with metastatic melanoma
harbouring a B-RAF V600E mutation and crizotinib in non-
small lung cancer patients with an EML-ALK transfusion
gene (Kwak et al., 2010; Flaherty et al., 2010). Logically, the
question has been raised whether also such promising drugs
should undergo the full traditional process of clinical testing
comprising phase I, phase II and phase III studies, a process
that on average takes 7 years to complete. And in case of the
absence of an appropriate standard therapy the ethics of ran-
domization may be questionable.
The fastest way to get approval for new treatments is
through the accelerated approval process. For agents that
are highly likely to benefit patients with life-threatening dis-
eases compared to available treatments, accelerated approval
can be obtained on the basis of surrogate endpoints for clinical
benefit such as response rate, DFS or (while considered the
most difficult to interpret by FDA) PFS, even in the context of
single-arm studies. Importantly, post-approval trials to con-
firm that the drug indeed yields clinical benefit are required.
In a recent review, FDA’s experiences with accelerated ap-
proval for new cancer drugs were described (Johnson et al.,
2011). From the initiation in December 1992 till July 2010, 35
new cancer drugs were approved for 47 different indications.
For 26 of these 47 indications regular approval were obtained
as clinical benefit could be confirmed in post-approval trials.
Clinical benefit could not be confirmed for three indications
leading to withdrawal of approval, while for the remaining
18 indications, post-approval trials were not completed (14 in-
dications) or under review at the time of writing the article
(four indications of which one, bevacizumab in metastatic
breast cancer, recently lost approval). The success of this pro-
gram is clear for agents for which activity could be subse-
quently confirmed and regular approval was obtained.
However, some major problems, that in particular may apply
to molecular targeted agents in selected populations, are less
obvious.
After accelerated approval, confirmatory trials should be
done in a timely-fashion. But because patients can get access
to the drug for their life-threatening disease, accrual for such
trials will be challenging and maybe even ethically question-
able. Additionally, molecular targeted agents are frequently
only active in very selected and thus rare tumors. Large trials
in the 5% of NSCLC patients with an EML-ALK translocation
will be still feasible because of the high incidence of NSCLC,
but impossible in other more rare tumor types. For example,
sunitinib and cediranib yield impressive outcomes in case se-
ries of patients with metastatic alveolar soft part sarcomas
(ASPS) (Gardner et al., 2009; Stacchiotti et al., 2009). However,
randomized trials will be hardly feasible in this tumor type,
even when these trials are aiming for a big improvement
M O L E C U L A R O N C O L O G Y 6 ( 2 0 1 2 ) 1 9 6e2 0 3202over another therapy and thus requiring relatively small num-
bers of patients. ASPS are extremely rare with in the USA an
annual incidence of approximately 90 new cases of which
the minority will get metastatic disease.
In addition to the problems on how to get regulatory ap-
proval swiftly, another topic that should be taken into account
when allowing a drug to the market are the costs. Molecular
targeted drugs are extremely expensive. Furthermore, large
numbers of patients need to be screened to identify the appro-
priate population using expensivemolecular assays. To endup
with 82 evaluable NSCLC patients with EML-ALK transloca-
tions, 1500 NSCLC patients needed to be screened (Kwak
etal., 2010). Asa consequence, the costs arebearable for society
when it concernsonly a fewdrugs and indications, butwith the
rapidly increasing number of agents and indications, this will
clearly become a major problem (Sleijfer and Verweij, 2009).
To overcome the problems mentioned above, Chabner re-
cently made an appeal for more flexible rules for accelerated
approval for molecular targeted cancer drugs without the
necessity of randomized trials with minimally effective com-
parators (Chabner, 2011). On the basis of his proposals with
some additions and alterations, novel criteria for approval
for cancer drugs could be: drugs that target a specific factor,
in a patient population for whom no effective treatments ex-
ists, which can be properly identified by a well-validated bio-
marker assay yielding high response rates (i.e. >50%), high
non-progression rates (i.e. >40%) at 6 months in patients
with objective tumor progression within 6 months before trial
entry, with an acceptable toxicity profile tested in a series of
75e100 patients. Additionally, the drug should be cost-
effective (i.e. maximum of 80,000 euros per 1 year PFS gained
compared to the PFS of the tested population before trial en-
try). Costs should also include the screening costs identify
the population of interest. After approval, subsequent trials
should focus on themost appropriate schedule, further refine-
ment to identify the population to treat, and combination
studies.8. Conclusion
With the emergence of the molecularly targeted agents and
the impressive antitumor activity that is nowadays seen in
early clinical trials, it is time to adapt our rules of trials design,
approval and registration. Hopefully, this will lead to faster
evaluation and approval of novel treatments and eventually,
improved cost-effectiveness of cancer treatment and better
outcomes for patients with cancer.R E F E R E N C E S
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